Find a Tender
complete
Official procurement procedure
Provision of Oncotype DX Breast Recurrence ScoreTM Assay
Medical equipments
pharmaceuticals and personal care products
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: BELFAST HEALTH AND SOCIAL CARE TRUST: "Provision of Oncotype DX Breast Recurrence ScoreTM Assay". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | BELFAST HEALTH AND SOCIAL CARE TRUST | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: BELFAST HEALTH AND SOCIAL CARE TRUST
Market Analytics
Derived from OCDS awards & bid statistics
Published history for BELFAST HEALTH AND SOCIAL CARE TRUST. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
Not availableNo published reports
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 0 active published awards; 0 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityBELFAST HEALTH AND SOCIAL CARE TRUST | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published28 Jun 2023, 10:42 BST | Last source update28 Jun 2023, 10:42 BST | Recurring procurementNot published |
ClassificationMedical equipments, pharmaceuticals and personal care products | ||
Delivery area | ||
OCIDocds-h6vhtk-03d509 | ||
What is being bought
Procurement of the Provision of Oncotype DX Breast Recurrence ScoreTM Assay
What changed
From the official release history
- Official notice release published
28 Jun 2023, 10:42 BST - Status changed to complete
9 Jun 2023, 12:15 BST - Official notice release published
9 Jun 2023, 12:15 BST - Buyer information updated
9 Jun 2023, 12:15 BST
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcancelledPublished valueNot publishedThe procurement for the Provision of Oncotype DX Breast Recurrence ScoreTM AssayContract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
28 Jun 2023, 10:42 BST - Award active
Not published · Not published - Contract active
Signed 26 Jun 2023, 00:00 BST · £450,000
Commercial outcome and competition
Awards Exact Sciences UK Ltd Not published · Not published · active |
Contracts Provision of Oncotype DX Breast Recurrence ScoreTM Assay £450,000 · signed 26 Jun 2023, 00:00 BST · active |
Bid statistics bids: 1 (lot 1) |
Buyer and organisations in this procedure
BELFAST HEALTH AND SOCIAL CARE TRUST
Contracting authority GB-FTS-4486Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleNo reasonable alternative exists for this procurement Provision of Oncotype DX Breast Recurrence Score Assay is available from only one economic operator and is essential for service delivery and patient care for breast cancer patients in Northern Ireland, the absence of competition is not the result of an artificial narrowing down of the parameters of this procurement. |